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bstract
A new UPLC method was developed for the simultaneous estimation of amoxicillin and chloramphenicol in pharmaceutical
ormulations. Drugs were resolved on Shim-Pack XR-ODS (2 mm i.d. ×  50 mm, particle size 2.2 m) reverse-phase column, utilizing
 mobile phase of methanol:0.0025 M ammonium acetate in the initial ratio 40:60 (v/v) at a gradient program. The mobile phase was
umped at a flow rate of 0.25 mL/min with detection at 220 nm. 10 L volume of sample was injected by the auto sampler. Separation
as completed within 2.72 ±  0.03 min. Calibration curves were linear with correlation coefficient 0.999 over a studied concentration
ange of 10 g mL−1 for both drugs. Method was found to be reproducible with relative standard deviation (RSD) for intra- and
nterday precision to be <1.5% over the said concentration range. The mean recovery of the drug from the standard solution was
9.39%. LOD was found to be 0.03 and 0.025 g mL−1 for amoxicillin and chloramphenicol, respectively. The proposed method
s simple, fast, accurate, precise and reproducible hence, it can be applied for routine quality control analysis of amoxicillin and
hloramphenicol in bulk and pharmaceutical formulations. Furthermore, study revealed that adverse drug interaction due to their
oncomitant use is not from pharmaceutical interaction.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
eywords: Antibiotic; UPLC method; Amoxicillin; Chloramphenicol; Drug interaction∗ Corresponding author. Tel.: +880 1710915011.
E-mail address: nasircu72@gmail.com (M.N. Uddin).
eer review under responsibility of Taibah University.
ttp://dx.doi.org/10.1016/j.jtusci.2015.11.005
658-3655 © 2015 The Authors. Production and hosting by Elsevier B.V. on 
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1.  Introduction
Amoxicillin (AMX) is a broad spectrum antibiotic
and is official in Indian pharmacopoeia, British Pharma-
copoeia, U.S.P. [1]. AMX penicillanate is used clinically
for the treatment of acute exacerbations of chronic bron-behalf of Taibah University. This is an open access article under the
chitis [2]. It is usually the drug of choice within the class
because it is better absorbed, following oral adminis-
tration, than other -lactam antibiotics. AMX acts by
inhibiting the synthesis of bacterial cell wall. Normally
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AMX is used for the treatment of common bacterial
infections both in humans and animals [3]. AMX is one
of the most common antibiotics prescribed for children.
It is on the WHO’s List of Essential Medicines. They are
normally the only penicillins added to feedstuffs at the
maximum level of 500 mg kg−1 [4].
Chloramphenicol (CLP) is an effective antibiotic that
has widely been used since the 1950s to treat food-
producing animals. CLP is a wide range antibiotic which
interferes with protein synthesis of many Gram-negative
and Gram-positive bacteria [5], and has toxic effects
on humans [6]. Miscellaneous toxic effects are due to
the dichloride carbon alpha to the carbonyl group; this
carbon readily undergoes substitution with nucleophiles
such as those found on proteins [7]. The main potential
human toxicity is depression of red blood cell produc-
tion in bone marrow leading to aplastic anemia [5,8]. Use
of intravenous CLP has also been associated with gray
baby syndrome, a phenomenon resulting from newborn
infants’ inability to metabolize CLP in the body. Other
less serious reactions include fever, rashes, headache
and confusion. CLP passes into breast milk, so should
therefore be avoided during breastfeeding, if possible.
Because of the well-known risk of aplastic anemia and
carcinogenic properties of CLP, its use in human and
veterinary medicine is limited by its toxicity [9].
Concomitant administration of AMX with CLP or
chemotherapeutics should be avoided as in  vitro  antag-
onism may occur due to their different mechanisms of
action. It may decrease the plasma level of estrogens
and progesterone, and may reduce the efficacy of oral
contraceptives. However, the clinical significance of this
interaction is not well documented. Thus, further exper-
iments are required to establish any interaction between
these drugs. It is reported earlier that there were adverse
drug interactions due to a pharmacodynamic interaction
[10]. Another drug interaction is pharmaceutical inter-
action which is aimed to be investigated.
In spite of its potential toxicity, CLP is sometimes
used at therapeutic doses for treatment of serious infec-
tions in humans. CLP is still widely used in topical
preparations (ointments and eye drops) for the treatment
of bacterial conjunctivitis. Even though use of CLP in
meat producing animals and aquaculture is banned in the
European Union (EU), Canada and United States, illegal
use of CLP to treat seafood products remains a possibility
due to its broad spectrum activity, ready availability and
low cost [11]. The minimum required performance limit
for the detection of CLP residues in food of animal origin
has been fixed at 0.3 g kg−1 [12]. Thus, a sensitive and
reliable method for the determination of CLP at resid-
ual levels is urgently needed. Adverse interaction in thersity for Science 10 (2016) 755–765
concomitant use of amoxicillin and chloramphenicol
may affect on their plasma level. Therefore their simul-
taneous determination in biosamples is of immense
importance. Attempts have been made to develop new
methods for the estimation of AMX and CLP in bulk,
pharmaceutical formulation, foods and biological fluids
with good precision, accuracy, linearity and repro-
ducibility.
Chromatographic techniques such as high-
performance liquid chromatography (HPLC) with
diode array detection [13,14] and gas chromatography
(GC) with electron capture detection have been used
[15,16]. GC–MS methods using either electron impact
(EI) or chemical ionization (CI) have been reported
[17,18], but these procedures still require a tedious
derivatization step prior to final analysis. Or, HPLC–MS
approaches high sensitivity competing to GC–MS
but still expensive. However, liquid chromatography
methods do not require a derivatization step.
Though there are a number of methods for their indi-
vidual determination but no method is available for
their simultaneous estimation in a single run. In this
paper UPLC method for simultaneous determination of
AMX and CLP in pharmaceutical formulation has been
reported. In addition study of adverse drug interaction
due to their concomitant use is investigated. The pro-
posed method is optimized and validated according to
ICH guidelines. This simple, accurate, precise and sen-
sitive method can also be used for the routine analysis
of both drugs in mixture without consuming time.
2.  Materials  and  methods
2.1.  Instrumentation
A Shimadzu (Kyoto, Japan) binary low-pressure
gradient system was used for the chromatographic deter-
mination of the examined analytes. The solvent lines
were mixed in an FCV-10ALVP mixer. An LC-30ADVP
pump equipped with a Shimadzu SCL-10ALVP Sys-
tem Controller, permitting fully automated operation,
was used to deliver the mobile phase to the analytical
column. Sample injection was performed via  a SIL-
30AC/Nexera auto sampler. Detection was achieved by
an SPD-M20AVP Photodiode Array Detector, complied
with Data acquisition software Lab Solutions-LC solu-
tions by Shimadzu. Degassing of the mobile phase was
achieved by passing helium in the solvent reservoirs by a
DGU-20 ASR degassing unit. The system was controlled
and data were analyzed, on a computer equipped with LC
solution software. The analytical column, a Shin-pack
XR-ODS (250 mm ×  2 mm, 2.2 m), was purchased
 Unive
f
v
t
f
c
b
E
2
s
S
t
i
s
E
w
h
s
A
(
(
p
2
w
d
m
a
w
m
s
c
c
s
m
b
2
g
e
w
u
c
a
p
iM.N. Uddin et al. / Journal of Taibah
rom MZ-Analysentechnik (Mainz, Germany). A glass
acuum-filtration apparatus obtained from Alltech (All-
ech Associates; Deerfield, IL, USA) was employed
or the filtration of the buffer solution, using 0.2 m
ellulose nitrate 0.2 m-WCN Type (47 mm DIA) mem-
rane filters (Whatman Laboratory Division, Maidstone,
ngland).
.2.  Materials
Amoxicillin and chloramphenicol (purity >99%)
tandard was purchased from Fluka (Buchs,
witzerland). Pharmaceutical formulations, capsules,
ablets, injections, ointment, and eye drops, available
n Bangladesh market were obtained from commercial
ources. HPLC-grade methanol was supplied by Carlo
rba (Milano, Italy). Water used throughout the study
as purified by the reverse osmosis method to gain
igh-purity water with a Milli-Q water purification
ystem from Millipore (Millipore, Bedford, MA, USA).
mmonium acetate was supplied from Riedel-de Haen
Buchs, SG, Switzerland). HPLC grade high purity
98.0%) acetaminophen used as internal standard was
urchased from Sigma–Aldrich.
.3.  Preparation  of  standards
Stock solutions of drugs and internal-standard (IS)
ere prepared at concentration level 100 ng L−1 by
issolving an appropriate amount of each compound in
ethanol and were stored at 4 ◦C, protected from light
nd used within 1 month. The stock solutions of drugs
ere further serially diluted daily before analysis with
ethanol to make interim mixture solutions (controlled
olution) at concentrations of 1.0–10.0 ng L−1 for each
ompound containing internal standard at a constant
oncentration of 2 ng L−1. Buffer: 0.025 M aqueous
olution of ammonium acetate buffer was prepared by
ixing appropriate weight in Milli-Q water and filtered
efore use.
.4.  Pharmaceutical  samples
Five tablets or the content of five capsules were finely
round and powdered. An accurately weighed portion
quivalent to 100 ng L−1 solution for each compound
as transferred to volumetric flask, dissolved and diluted
p to the mark with methanol. The solution was soni-
ated for 15 min and centrifuged at 3000 rpm for 10 min,
nd filtered through a 0.2 m filter with Whatman filter
aper. An aliquot portion of a commercially available
njection vial, eye drops were transferred to volumetricrsity for Science 10 (2016) 755–765 757
flask, diluted with methanol as to provide a stock solu-
tion of 100 ng L−1. All stock solutions were stored at
4 ◦C in refrigerator. Dilution has been made to accurately
measured aliquots of the stock solution with methanol to
give working concentrations of individual analyte each
containing 2.0 ng L−1 internal standards.
2.5.  Preparation  of  calibration  curves
Calibration curves were prepared for seven concen-
tration levels ranged from 1.0 to 10.0 ng L−1 of each
analyte for standard mixture containing a volume to be
equivalent to 2 ng L−1 of internal standard (IS). The
calibration curves were constructed by plotting peak
area ratios of corresponding analytes to the internal
standard against their theoretical concentrations which
were fitted by a least squares linear regression to the
equation: response ratio (y) = slope (m) ×  concentration
(x) + intercept (c). Unknown concentrations of analytes
were determined with reference to the calibration equa-
tion.
2.6.  Chromatographic  conditions
A standard solution at concentration level 5 ng L−1
was used for the optimization procedure. Reversed-
phase Shin-pack XR-ODS (250 mm ×  2 mm, 2.2 m)
column and 0.025 M CH3COONH4 as buffer solution
all through the experiment were used to study the simul-
taneous separation of both drugs in presence of IS. To
evaluate an efficient UPLC method special attention was
given on optimization of the mobile phase composi-
tion to obtain satisfactory results with good resolution
at reduced elution time and tailing problems. Several
solvent gradients were performed to determine the opti-
mum one to detectable peaks with high resolution in
the chromatogram at considerable analysis time. An UV
scan of standard solution in the used mobile phase was
done for the spectra of studied drugs in the range of
200–400 nm to detect the absorption maxima. The best
flow rate was investigated with respect to sharpness and
symmetry of the peaks. Under the above considerations
mobile phase under gradient program as presented in
Table 1 was supplied as the optimized conditions at a
flow rate of 0.25 mL/min at ambient temperature. The
injection volume was 10 L. Prior to the analysis the
column was equilibrated with mobile phase by the ini-
tial ratio of 40:60 (v/v). The ammonium acetate solution
was filtered in vacuum using 0.2 m membrane, and the
mobile phase was degassed prior to use by a stream of
helium.
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Table 1
Optimum gradient program for the proposed method.
Program Time Solvent Flow rate (mL/min) R. time (min)
CH3OH 0.025 M CH3COONH4
Aa 0.01 40.0 60.0 0.25 2.7
1.00 35.0 65.0
2.00–3.500 45.0 55.0
B 0.01 45.0 55.0 0.27 2.52
1.00 40.0 60.0
2.00–3.500 50.0 50.0
a Program has been followed throughout the experiment.
3.  Validation  parameters
Method was validated in terms of ICH [19] ana-
lytical performance parameters: precision, accuracy,
specificity, limit of detection, limit of quantitation, lin-
earity and range, suitability and robustness.
3.1.  Linearity
Linearity was determined by constructing the calibra-
tion curves for standard samples at certain concentration
levels. Each concentration was analyzed in triplicate and
curves were constructed using peak area ratio of drug to
the internal standard versus  nominal concentrations of
the analytes. Least square linear regression analysis of
the data gave slope, intercept, and correlation coefficient
or coefficient of determination.
3.2.  Recovery/accuracy
Aliquots of 10 L of the selected assay solutions at
three concentration levels were injected into the UPLC
system, and triplicate measurements were recorded for
each concentration. The nominal contents of the drug in
each solution were calculated from the linear regression
equations. The results were expressed as percent recover-
ies of the particular components in the samples as [mean
found concentration/theoretical concentration] × 100.
3.3.  Precision
The precision, degree of repeatability of the method,
was determined by calculating the standard deviation
(SD) and the relative standard deviation (RSD) for the
repeated measurements between nominal and measured
concentrations by analyzing different concentrations.
Intraday and interday precision and accuracy of the
assay were assessed by performing replicate analyses
of drugs in standard solutions against a calibrationcurve. Intraday repeatability was determined in six
replicates at three concentrations levels of drugs of
standard in the same day. The procedure was repeated
on six consecutive days, in standard samples at same
concentration levels, to determine interday repeatability.
3.4.  Speciﬁcity/selectivity
The specificity is the ability to measure accurately and
specifically the analyte of interest in the presence of other
components that may be expected to be present in the
sample matrices. It was demonstrated that analytes were
free of interference from degradation products or excip-
ients in pharmaceutical formulations ensuring that peak
response in the same retention times is due to examined
components only.
3.5.  Sensitivity
Sensitivity of the method has been tested by examin-
ing limit of detection (LOD), the lowest concentration of
an analyte in a sample that can be detected but not nec-
essarily quantified, and the limit of quantitation (LOQ),
the lowest concentration of analyte in a sample that can
be determined with acceptable precision and accuracy
under the stated operational conditions of the method.
The calculation method is based on the standard devia-
tion of the response (Sxy) and the slope of the calibration
curve (a). The limit of detection was calculated from cal-
ibration graph by the formula: LOD = 3·Sxy/a, and the
limit of quantification: LOQ = 10·Sxy/a.
3.6.  Stability
The stability of both drugs in mixture solutions was
tested by the proposed method over a period of 60 days
for long-term assay. The freshly prepared solutions at
room temperature and the 60 days stored solutions in
a refrigerator at both 4 ◦C and −20 ◦C were analyzed.
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ach sample was analyzed for intact compounds once
aily for investigation of stability. Recovery and RSD of
he stored samples were calculated and compared to that
f freshly prepared samples.
.7.  Robustness
Robustness is the capacity of the method to remain
naffected by small deliberate variations in method
arameters. It has been evaluated by varying method
arameters set for optimum conditions such as flow rate,
radient program, concentration of buffer, and determin-
ng the effect (if any) on the results of the method.
.8.  Column  efﬁciency
The column efficiency parameters have been
alculated for a representative chromatogram by
he relations: retention factor, k = tR −  t0/t0, sepa-
ation factor, α  = tR2 −  t0/tR1 −  t0, resolution factor,
s = 2(tR2 −  tR1)/(w1 + w2), theoretical plate num-
er, N  = 16(tR/w)2 and tailing or asymmetry factor,
f = (a  + b)/2a, where t0, tR1 and tR2 are the retention
imes and w1 and w2 the baseline peak width of
uccessive peaks.
.  Results  and  discussion
.1.  Chromatography
The chromatographic conditions optimized were
omposition of the solvents, and mobile phase flow rate.
obile phase must elute the substances with satisfac-
ory peak shape in a short time. Initial experiments with
he LC system using methanol or acetonitrile as organic
odifier in the buffered mobile phase were performed
or better separation of analytes. The combination
f methanol with 0.025 M ammonium acetate served
ur intentions best. Reversed-phase Shin-pack XR-
DS (250 mm ×  2 mm, 2.2 m) column and 0.025 M
H3COONH4 as buffer solution all through the exper-
ment were used to study the simultaneous separation
f both drugs in presence of IS. In particular, peak tail-
ng observed was considerable. In order to determine
he detection wavelength, the absorption spectra of all
ompounds were obtained. The absorption spectra of all
ompounds showed absorption bands in the UV region
ith maximum absorption wavelengths ranged between
10 and 245 nm (Fig. 1). Therefore, 220 nm selected
or monitoring as compromised to the both drugs. To
etermine the optimum mobile phase flow rate under
ptimized composition the effect on Rt, peak height andFig. 1. Electronic spectra of amoxicillin (lower) and chloramphenicol
(upper) standard solution in the used mobile phase.
peak width, and Rs was studied. As expected when the
mobile-phase flow rate was increased Rt and Rs of all
the compounds decreased. A flow rate of 0.25 mL/min
was chosen as a compromise between Rs and analysis
time, because this value also maintains good peak shape.
The mobile phase, mixture of CH3OH and 0.025 M
CH3COONH4 was used at gradient program equilibrated
initially by 40:60 (v/v). The method was carried out
for the simultaneous detection and quantitation of both
drugs representing improved separation in total elution
time less than 3 min (2.72 ±  0.03 min). A representa-
tive chromatogram as shown in Fig. 2 was obtained
from a standard mixture solution under optimized condi-
tions. This chromatogram showed appropriate resolution
(Rs = 1.7–1.92) between the compounds investigated. No
interfering of peaks was observed in the samples stud-
ied. But both drugs were simultaneously determined with
no influence on their selectivity. Precision of retention
times was examined to evaluate system suitability from
within-day repeatability (mean value of six measure-
ments, n  = 18) and between-day  precision (mean value of
three measurements during six days, n = 54) at 3, 5 and
7 ng mL−1 level of drugs, which revealed RSD values of
0.47–1.33%.
The validated method developed herein was applied
to various concentrations taken from the pharmaceuti-
cal products for determining the content of investigated
drugs. Table 2 summarizes intraday and interday pre-
cision and accuracy data, indicating that these values
are acceptable and the method is accurate and precise.
Analytical data of system suitability and robustness in
Table 3 are placed. Table 3 also shows the column effi-
ciency data as the validation evidence. Table 4 presents
the analytical values on pharmaceutical formulations.
Supplementary data 1 shows the results of this method
compared with other reported methods. It confirms that
developed method is suitable over existing methods.
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Fig. 2. Typical UPLC chromatogram of the two examined drugs (5 ng mL−1) in standard in the presence of IS (2 ng mL−1). Chromatographic
conditions are described in text. Peaks: 0.75 min (AMX), 1.48 min (IS), and 2.63 min (CLP).
Table 2
Summarizes within-day and between-day precision and accuracy data.
Analytes Added value
(g mL−1)
Intraday analysis Interday analysis
Found value
(g mL−1)
RSD (%) Recovery
(%)
Found value
(g mL−1)
RSD (%) Recovery
(%)
AMX 3 2.93 ± 0.11 1.93 97.59 2.99 ± 0.39 2.11 99.80
5 5.38 ± 0.23 2.53 107.76 5.35 ± 0.32 2.50 107.1
7 7.11 ± 0.34 2.40 101.52 6.57 ± 0.50 2.51 93.80
9 8.88 ± 0.08 0.51 98.74 8.88 ± 0.08 1.54 97.76
CLP 3 2.91 ± 0.16 2.45 98.91 2.97 ± 0.42 2.17 98.86
5 5.30 ± 0.26 2.22 105.99 5.27 ± 0.32 2.54 105.37
7 7.40 ± 0.40 2.19 105.77 6.74 ± 0.63 2.51 96.33
9 8.83 ± 0.09 0.65 98.14 8.61 ± 0.19 1.33 95.63
Table 3
Validation parameters in terms of suitability, robustness and column efficiency.
Analytes Suitability Robustness (% recovery)
Rt (RSD) A. ratio (RSD) Program A Program B
FR (0.25 mL/min) FR (0.25 mL/min) FR (0.27 mL/min)
AMX 0.47 1.71 102.07 101.61 102.08
CLP 1.33 1.07 102.21 100.32 101.17
Analytes Retention factor Separation factor Resolution factor Asymmetry factor
k = (tR − t0) α = k2/k1 Rs = 2(tR2 − tR1)/(w1 + w2) Tf = (a + b)/2a
AMX 0.75 – – 1.5
IS 1.15 0.66 1.17 1.2
CLP 2.62 2.28 1.92 1.4
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Table 4
Determination of amoxicillin and chloramphenicol in pharmaceutical formulations by the proposed method.
Formulation
AMX
Added
value
Exp.
conc.
RSD
(%)
Mean
R (%)
Formulation
CLP
Added
value
Exp.
conc.
RSD
(%)
Mean R
(%)
g mL−1 g mL−1
Capsule Eye drops
Moxacil 3 3.11 ± 0.10 1.73 A-Phenicol 3 3.13 ± 0.03 1.06
5 4.39 ± 0.36 4.64 95.51 5 5.18 ± 0.04 0.70 101.22
7 6.65 ± 0.07 0.63 7 6.69 ± 0.07 1.04
Fimoxyl 3 3.12 ± 0.23 4.01 Cloram 3 2.75 ± 0.07 2.49
5 4.81 ± 0.30 3.59 101.28 5 4.53 ± 0.14 3.12 91.252
7 7.24 ± 0.22 1.78 7 6.40 ± 0.02 0.39
Moxillin 3 3.10 ± 0.15 2.62 Ocutrex 3 2.82 ± 0.05 1.79
5 5.19 ± 0.10 1.16 100.46 5 4.44 ± 0.05 1.16 86.80
7 6.60 ± 0.51 4.57 7 5.43 ± 0.02 0.36
Sinamox 3 3.18 ± 0.09 2.73 ICOL 3 2.60 ± 0.69 2.80
5 5.16 ± 0.16 3.12 102.39 5 4.74 ± 0.05 1.00 88.91
7 6.87 ± 0.15 2.16 7 5.97 ± 0.04 1.56
Tycil 3 3.24 ± 0.01 0.39 Chlorophen 3 2.88 ± 0.03 0.90
5 4.97 ± 0.18 3.67 100.86 5 4.47 ± 0.07 1.67 88.24
7 6.65 ± 0.24 3.66 7 5.56 ± 0.05 0.96
Avlomox 3 3.13 ± 0.06 1.94 Optaphenicol 3 1.65 ± 0.09 5.18
5 5.22 ± 0.15 2.90 103.20 5 2.32 ± 0.08 3.42 47.70
7 7.07 ± 0.08 4.87 7 2.93 ± 0.02 0.52
Amotid 3 3.15 ± 0.07 2.11 Supraphen 3 1.92 ± 0.03 1.33
5 5.13 ± 0.04 6.55 102.21 5 3.68 ± 0.07 1.81 71.75
7 6.93 ± 0.24 3.49 7 5.43 ± 0.02 0.44
SK mox 3 3.15 ± 0.03 0.11 Optabac 3 1.99 ± 0.05 2.45
5 5.27 ± 0.07 1.28 103.41 5 3.84 ± 0.03 0.82 74.59
7 6.99 ± 0.24 0.63 7 5.64 ± 0.01 0.15
Moxin 3 3.23 ± 0.09 2.65 SQ mycetine 3 3.08 ± 0.01 0.46
5 4.79 ± 0.06 1.23 103.76 5 4.76 ± 0.15 3.25 98.43
7 7.53 ± 0.09 1.24 7 6.82 ± 0.09 1.29
Tablet Opsophenicol 3 2.50 ± 0.13 5.47
Bectamox 3 3.08 ± 0.28 9.12 5 4.37 ± 0.06 1.45 87.20
5 5.24 ± 0.08 1.44 100.41 7 6.35 ± 0.08 1.34
7 6.55 ± 0.14 2.21 Ointment
Avlomox 3 2.12 ± 0.11 5.47 Supraphen 3 2.88 ± 0.09 3.12
5 3.51 ± 0.21 6.09 69.03 5 4.93 ± 0.17 3.42 97.89
7 4.65 ± 0.08 1.73 7 6.95 ± 0.27 3.80
Injection Injection
Moxilin 3 3.12 ± 0.02 0.33 Optichlor 3 1.82 ± 0.02 0.57
4
c
p
t
m
d
s
a
a
a5 5.18 ± 0.06 0.67 101.74 
7 6.85 ± 0.11 0.99 
.2.  Application  to  pharmaceutical  formulations
The method developed here was applied to various
oncentrations (3.0, 5.0, and 7.0 ng L−1) of solutions
repared from pharmaceutical products for determining
he content of AMX and CLP. Typical UPLC chro-
atogram of the two examined drugs (7 ng mL−1) in
rug formulation in the presence of IS (2 ng mL−1) is
hown in Fig. 3. The values of the overall drug percent-
ge recoveries and the RSD values of measurements are
s presented in Table 4. Results indicate that these values
re acceptable and the method is accurate and precise.5 3.46 ± 0.06 0.91 67.96
7 5.17 ± 0.06 0.64
Recovery was almost same as that of leveled values. In
case of eye drops recovery was lower than leveled val-
ues for all products. Moreover determination was free
of interference from degradation products and no inter-
ference from the sample excipients could be observed at
this detection wavelength, indicating the high specificity
of the method.4.3.  Method  validation
The described UPLC method was developed using a
simple mobile phase to provide a rapid quality control
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conditions are described in text. Peaks: 0.75 min (AMX), 1.48 min (IS
determination of both drugs in standard and pharmaceu-
tical formulations. The parameters linearity, selectivity,
extraction recovery, precision, accuracy, stability and
robustness were studied for the validation of the method.
4.3.1. Linearity
The calibration curves constructed for standard using
working concentration at levels 3.0, 5.0, 7.0, 9.0, and
10.0 ng L−1 of each drug containing IS equivalent to
2 ng L−1 each. Calibration curves were constructed
using peak area ratio of drug to the internal standard
versus nominal concentrations of the analytes. Cali-
bration equations are y  = 1.558x  + 0.902 for AMX and
y = 1.551x  + 1.065 for CLP determination. The calibra-
tion curves were linear in the range of 0.2–10 ng L−1
for both AMX and CLP. The coefficients of determina-
tion (r2) were 0.999 for both drugs.
4.3.2. Sensitivity
The LOD and LOQ were 0.03 and 0.10 ng L−1 for
AMX and 0.025 and 0.080 ng L−1 for CLP, respec-
tively for standard samples. These results indicate that
method is sensitive enough for therapeutic assay.
4.3.3. Recovery
The results of recovery studies obtained from theintraday assay at three concentrations (n  = 6) by the pro-
posed method was 97–107% and interday assay at six
different days was 95–107% indicated high recoveries
of both drugs. drug formulation in the presence of IS (2 ng mL−1). Chromatographic
.63 min (CLP).
4.3.4.  Precision/accuracy
The relative standard deviations (RSD) obtained for
the intraday assay at three concentrations (n  = 6) in the
range 0.5–2.5% for AMX and 0.65–2.9% for CLP and
for interday assay the corresponding values in the range
1.5–7.1% for AMX and 1.3–5.5% for CLP indicating
the high precision of the method. Intraday and inter-
day recovery and precision data for proposed method
are presented in Table 2.
4.3.5. Speciﬁcity
The specificity was demonstrated showing that drugs
was as well as IS determined free of interference from
potential impurities and degradation products absence of
any peak in the same retention times. Results indicate the
high specificity of the method and can be used in a sta-
bility assay and routine analysis of the both investigated
drugs.
4.3.6. Robustness
It was found that the percent recoveries were excellent
under most conditions, and remained unaffected by small
deliberate changes of experimental parameters includ-
ing the flow rate and gradient program (Table 3) though
retention time and resolution was decreased as expected.
Variation in the experimental parameters (flow rate, gra-
dient program) provided an indication of its reliability
during normal use and concluded that the method was
robust.
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.3.7.  System  suitability
The system suitability was assessed by replicate
njections of the sample at three concentration lev-
ls including within- and between-day assessments for
tandard. Precision of retention time and peak area ratios
as examined to evaluate the system suitability. RSD of
he peak area ratios 1.07–1.71% and that of retention
ime 0.47–1.33% indicates excellent suitability of the
ystem as shown in Table 3.
.3.8. Stability
Stability of both AMX and CLP in methanol was
hecked during seven days at room temperature in dry
nd dark place and refrigerated at 4 ◦C and −20 ◦C.
ecoveries of each compound were ≥99.6% up to one
Fig. 5. Long term stability grapraph for amoxicillin.
week at room temperature. 4 ◦C stored sample showed
rapid decrease after 10 days. Results conclude that there
was no degradation product and the drug is stable at
−20 ◦C for at least 60 days, indicating the possibility of
using the samples over a period of 30 days at refrigera-
tor without degradation as shown in Figs. 4 and 5. This
indicates good stability.
4.3.9.  Column  efﬁciency
The column efficiency parameters have been calcu-lated for a representative chromatogram. The calculated
values: retention factor, k  = 1.1–4.8, separation factor,
α = 1.1–1.8, resolution factor, Rs = 0.7–4.3, theoretical
plate number, and tailing factor, Tf = 1.0–1.5 shown in
h for chloramphenicol.
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Table 5
Comparison of recovery of concomitant application to their individual determination.
Analytes Added value
(g mL−1)
Combined estimation (n = 10) Individual estimation (n = 10) % of variation
Conc. (g mL−1) RSD %R Conc. (g mL−1) RSD %R
AMX
3 3.09 1.23 103.2 3.09 1.13 103.12 −0.12
5 4.99 1.06 99.93 5.01 1.56 100.11 −0.52
7 7.1 1.84 101.51 7.06 1.24 100.91 1.21
CLP
3 3.08 1.93 103.01 3.07 1.83 102.51 0.152
5 5.11 1.81 102.26 5.10 1.61 101.98 0.327
100.477 7.03 1.45 
Table 3 revealed the excellent performance of analytical
column.
5.  Drug  interactions
AMX acts by inhibiting bacterial cell wall synthesis.
CLP slows growth of bacteria by preventing them from
producing important proteins that they need to survive.
There are no data on the incompatibility of amoxicillin
and other drugs. AMX has an impact only on reproducing
organisms, so they should not be combined with bac-
teriostatic antibiotics, such as CLP. CLP may interfere
with the bactericidal effects of penicillin. This has been
demonstrated in  vitro; however, the clinical significance
of this interaction is not well documented.
The drug interaction was investigated for the con-
comitant use of amoxicillin and chloramphenicol when
experiments were done on respective pediatric patients.
Authors reported that there were adverse drug inter-
actions due to a pharmacodynamic interaction [10].
Another type of adverse drug interaction is pharmaceuti-
cal interaction. Table 5 shows the comparison of recovery
of concomitant application to their individual determi-
nation. Present investigation shows that both drugs have
been determined simultaneously in their mixture with-
out any interference from drug degradation. From the
comparison of chromatogram of both drugs obtained in
a single run it is evident that no pharmaceutical interac-
tion has been occurred in their combined determination.
Furthermore, presence of no additional peak or no loss
of the drug concentration confirms that no interaction
is happened. No evidences of degradation or interfer-
ences was detected our present condition with in study
range or retention time. Acceptable recover and excellent
precision of the measurements were obtained indicating
that drug interaction does not suppose due to physico-
chemical interaction in which the physical and chemical
reactions occur between drugs that alter or eliminate the
pharmacological activity of the drugs. The adverse drug 7.01 1.75 100.04 0.91
interactions are a pharmacodynamic interaction in the
concomitant use of AMX and CLP (21.73%) which may
reduce the efficacy of AMX [10]. This adverse inter-
action could reduce plasma level of amoxicillin in the
plasma, thus decrease its efficacy. Further research is
required for the confirmation of this interaction. The
interaction could cause antagonistic effect as the CLP
works by inhibiting bacterial protein synthesis and could
change the active growth of bacterial colonies to be static.
This could cause the bactericidal effect of amoxicillin to
be obstructed and bacterial killing becomes slower.
6.  Conclusion
The method described enables the simultaneous
quantification of amoxicillin and chloramphenicol in
mixture. The validation data demonstrate good preci-
sion and accuracy, which prove the reliability of the
proposed method. Hence, this UPLC method can be
used routinely for quantitative estimation of both com-
ponents in mixture form. This study demonstrates the
applicability of the proposed method for the potency
determination of amoxicillin and chloramphenicol in
bulk drug and pharmaceutical formulations. The method
can be successfully used for routine quality control and
stability assays and offers advantages in speed, sim-
plicity, and reliability. Study also confirms that adverse
drug interactions are supposed to be due to pharmacody-
namic interaction rather than pharmaceutical interaction
in the concomitant use of AMX and CLP. Method might
be applied for their simultaneous determination in bio-
logical samples having isolated followed by a suitable
extraction procedure.
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